The Efficacy of Panitumumab Plus Chemotherapy As Initial Treatment for KRAS Wild-Type Unresectable, Metastatic Colorectal Cancer: A GRADE-Approach Systematic Review and Meta-Analysis

Previous PostAre There Intersections in Evidence Requirements for Health Technology Assessment Agencies across North America, Europe and the Asia-Pacific?
Next PostLeber hereditary optic neuropathy: utilities and carer burden from British and Irish participants

© Copyright 2025 Initiate Consultancy is a limited company.
Registered in England and Wales. Reg No. 11903774 | Privacy Policy

Let’s discuss your purpose

hello@initiateconsultancy.com